DSM Capital Partners LLC Sells 431,273 Shares of DexCom, Inc. $DXCM

DSM Capital Partners LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 18.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,923,820 shares of the medical device company’s stock after selling 431,273 shares during the period. DexCom comprises 2.1% of DSM Capital Partners LLC’s holdings, making the stock its 14th biggest position. DSM Capital Partners LLC’s holdings in DexCom were worth $120,816,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of DXCM. Trust Co. of Vermont increased its holdings in shares of DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after purchasing an additional 145 shares during the period. CVA Family Office LLC raised its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares during the period. Essex Financial Services Inc. boosted its stake in shares of DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the period. Finally, IFP Advisors Inc grew its position in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares in the company, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,450 shares of company stock worth $5,270,409 in the last ninety days. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $74.06 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The stock has a market capitalization of $28.58 billion, a P/E ratio of 31.65, a price-to-earnings-growth ratio of 1.21 and a beta of 1.45. The stock has a fifty day moving average of $68.99 and a 200-day moving average of $68.34.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.32 EPS. On average, sell-side analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on DXCM. TD Cowen restated a “buy” rating and set a $95.00 price objective (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Piper Sandler reiterated an “overweight” rating and set a $88.00 target price (up from $75.00) on shares of DexCom in a research report on Monday, June 15th. William Blair raised DexCom to a “strong-buy” rating in a report on Friday, May 15th. UBS Group set a $95.00 price objective on shares of DexCom in a research report on Wednesday, June 10th. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $84.88.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.